Insider Buying: The ZIVO Bioscience, Inc. (NASDAQ:ZIVO) Independent Director Just Bought 13% More Shares

Potential ZIVO Bioscience, Inc. (NASDAQ:ZIVO) shareholders may wish to note that the Independent Director, Christopher Maggiore, recently bought US$340k worth of stock, paying US$3.72 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 13%.

Check out our latest analysis for ZIVO Bioscience

ZIVO Bioscience Insider Transactions Over The Last Year

Notably, that recent purchase by Independent Director Christopher Maggiore was not the only time they bought ZIVO Bioscience shares this year. Earlier in the year, they paid US$4.99 per share in a US$499k purchase. That means that an insider was happy to buy shares at above the current price of US$3.76. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

ZIVO Bioscience insiders may have bought shares in the last year, but they didn't sell any. Their average price was about US$4.29. This is nice to see since it implies that insiders might see value around current prices. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

ZIVO Bioscience is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does ZIVO Bioscience Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 11% of ZIVO Bioscience shares, worth about US$3.8m, according to our data. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Do The ZIVO Bioscience Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that ZIVO Bioscience insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing ZIVO Bioscience. Every company has risks, and we've spotted 5 warning signs for ZIVO Bioscience (of which 3 can't be ignored!) you should know about.

Of course ZIVO Bioscience may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.